Next Article in Journal
Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review
Next Article in Special Issue
mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn’s Disease
Previous Article in Journal
Long Non-Coding RNAs Target Pathogenetically Relevant Genes and Pathways in Rheumatoid Arthritis
Previous Article in Special Issue
Mesenchymal Stem Cells for Perianal Crohn’s Disease
Article Menu

Export Article

Open AccessArticle

Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs

1
IBD Unit, Humanitas Research Hospital, 20089 Milan, Italy
2
Department of Chemistry G. Ciamician, Alma Mater Studiorum University of Bologna, 40100 Bologna, Italy
3
Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Ioannina School of Health Sciences, 45110 Ioannina, Greece
4
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy
*
Author to whom correspondence should be addressed.
Cells 2019, 8(8), 817; https://doi.org/10.3390/cells8080817
Received: 21 June 2019 / Revised: 24 July 2019 / Accepted: 1 August 2019 / Published: 2 August 2019
  |  
PDF [2188 KB, uploaded 12 August 2019]
  |  

Abstract

Background: Inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD), represent systematic chronic conditions with a deficient intestinal absorption. We first attempt to investigate the serum bile acids (sBAs) profile in a large cohort of IBD patients to evaluate changes under anti-TNF alpha treatment. Methods: Forty CD and 40 UC patients were enrolled and BAs were quantified by high-pressure liquid chromatography-electrospray-tandem mass spectrometry (HPLC-ES-MS/MS). Up to 15 different sBAs concentrations and clinical biomarkers where added to a Principal Component Analysis (PCA) to discriminate IBD from healthy conditions and treatment. Results: PCA allowed a separation into two clusters within CD (biologic-free patients and patients treated with anti-TNF alpha drugs and healthy subjects) but not UC. The first included CD. CD patients receiving anti-TNF alpha have an increase in total sBAs (4.11 ± 1.23 μM) compared to patients not exposed. Secondary BAs significantly increase after anti-TNF alpha treatment (1.54 ± 0.83 μM). Furthermore, multivariate analysis based on sBA concentration highlighted a different qualitative sBAs profile for UC and CD patients treated with conventional therapy. Conclusion: According to our results, anti-TNF alpha in CD restores the sBA profile by re-establishing the physiological levels. These findings indicate that, secondary BAs might serve as an indirect biomarker of the healing process. View Full-Text
Keywords: Crohn’s disease; ulcerative colitis; absorption; bile acids; secondary bile acids Crohn’s disease; ulcerative colitis; absorption; bile acids; secondary bile acids
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Roda, G.; Porru, E.; Katsanos, K.; Skamnelos, A.; Kyriakidi, K.; Fiorino, G.; Christodoulou, D.; Danese, S.; Roda, A. Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs. Cells 2019, 8, 817.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top